A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

The EXPErimental medicine Route To Success in ALS (EXPERTS-ALS) project aims to rapidly screen potential drugs for evidence that they can slow down damage to the nervous system occurring in people wit ...

we believe AMX0114 has the potential to be a treatment for ALS and other diseases,” Amylyx Chief Medical Officer Camille Bedrosian, M.D., said in the release. The investigational antisense ...

Fifteen U.S. nonprofit organizations formed a new ALS group, ALS United, to help address the needs of people living with ALS.

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.

Individuals living with ALS are automatically eligible for Medicare when they start receiving Social Security benefits. Medicare should cover most diagnostics and treatments, but this depends on the ...

Nader Yaghoubi, M.D., Ph.D., PathMaker’s Co-Founder and CEO, stated, “We are pleased to announce IRB approval for the CALM study, which allows us to commence enrollments shortly. Given the mechanisms ...

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The ...